Correlation between microRNA‑21 and sprouty homolog 2 gene expression in multiple myeloma

Wang,Jin‑Hang; Zheng,Wen‑Wen; Cheng,Shi‑Tong; Liu,Bo‑Xin; Liu,Fu‑Rong; Song,Jian‑Qing

doi:10.3892/mmr.2015.3280

Correlation between microRNA‑21 and sprouty homolog 2 gene expression in multiple myeloma

Authors:
- Jin‑Hang Wang
- Wen‑Wen Zheng
- Shi‑Tong Cheng
- Bo‑Xin Liu
- Fu‑Rong Liu
- Jian‑Qing Song
View Affiliations

Affiliations: Laboratory Department of the First Affiliated Hospital of China Medical University, China Medical University School of Medicine Based in Shenyang, Teaching and Research Section of Cell Biology, Shenyang, Liaoning 110001, P.R. China
Published online on: January 29, 2015 https://doi.org/10.3892/mmr.2015.3280
Pages: 4220-4224
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the expression level of microRNA 21 (miR‑21) in the peripheral blood of patients with multiple myeloma (MM) and to investigate the correlation between miR‑21 and sprouty homolog 2 (SPRY2) gene expression levels in MM. A total of 30 patients with MM, 15 with monoclonal gammopathy of undetermined significance (MGUS) and 20 normal control (NC) outpatients were selected for the detection of miR‑21 and SPRY2 expression using reverse transcription-quantitative polymerase chain reaction. In addition, western blot analysis was performed to detect the expression of miR‑21 and SPRY2 in MM cell lines. The expression of miR‑21 in U‑266 cells following lipofectamine transfection of fluorescence‑labeled miR‑21 mimic/inhibitor was observed using a fluorescence microscope and the expression level of SPRY2 in the miR‑21 mimic/inhibitor‑transfected U‑266 cells was detected using western blot analysis. The miR‑21 expression level in the circulating serum of the MM patient group was significantly higher (P<0.01) than that of the MGUS and NC groups. The MM cell lines with high endogenous miR‑21 expression exhibited an expression level of SPRY2 that was significantly lower than that in the MM cells with low endogenous miR‑21 expression. The transfection efficiency of fluorescence‑labeled miR‑21 mimic/inhibitor was >90%. Compared with the miR‑21 expression level in untreated U‑266 cells (0.82±0.13), the expression level of miR‑21 was increased by 120.2‑fold in miR‑21 mimic‑transfected cells (98.6±14.2; P<0.001) and was decreased by 61.9% in the miR‑21 inhibitor‑transfected cells (0.37±0.06; P<0.05). The grayscale value of protein bands demonstrated that SPRY2 protein expression significantly decreased in miR‑21 mimic‑transfected U‑266 cells compared with that in the inhibitor‑transfected, siRNA‑transfected and untreated cells (P<0.01). miR‑21 may represent a negative regulator involved in the downregulation of SPRY2 in MM. miR‑21 is closely associated with the pathogenesis, progression and prognosis of MM and may thus be used as an indicator of poor MM prognosis.

View Figures

View References

1	Hatzimichael E, Dasoula A, Benetatos L, Syed N, Dranitsaris G, Crook T and Bourantas K: Study of specific genetic and epigenetic variables in multiple myeloma. Leuk Lymphoma. 51:2270–2274. 2010. View Article : Google Scholar : PubMed/NCBI
2	Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, Drandi D, Taccioli C, Zanesi N, Alder H, Hagan JP, et al: MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA. 105:12885–12890. 2008. View Article : Google Scholar : PubMed/NCBI
3	Edwin F, Anderson K, Ying C and Patel TB: Intermolecular interactions of sprouty proteins and their implications in development and disease. Mol Pharmacol. 76:679–691. 2009. View Article : Google Scholar : PubMed/NCBI
4	Feng YH, Wu CL, Shiau AL, Lee JC, Chang JG, Lu PJ, Tung CL, Feng LY, Huang WT and Tsao CJ: MicroRNA-21-mediated regulation of Sprouty2 protein expression enhances the cytotoxic effect of 5-fluorouracil and metformin in colon cancer cells. Int J Mol Med. 29:920–926. 2012.PubMed/NCBI
5	Lao DH, Chandramouli S, Yusoff P, et al: A Src homology 3-binding sequence on the C terminus of Sprouty2 is necessary for inhibition of the Ras/ERK pathway downstream of fibroblast growth factor receptor stimulation. J Biol Chem. 281:29993–30000. 2006. View Article : Google Scholar : PubMed/NCBI
6	Sayed D, Rane S, Lypowy J, He M, Chen IY, Vashistha H, Yan L, Malhotra A, Vatner D and Abdellatif M: MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths. Mol Biol Cell. 19:3272–3282. 2008. View Article : Google Scholar : PubMed/NCBI
7	Leone E, Morelli E, Di Martino MT, Amodio N, Foresta U, Gullà A, Rossi M, Neri A, Giordano A, Munshi NC, et al: Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. Clin Cancer Res. 19:2096–2106. 2013. View Article : Google Scholar : PubMed/NCBI
8	Shah AA, Leidinger P, Blin N and Meese E: miRNA: small molecules as potential novel biomarkers in cancer. Curr Med Chem. 17:4427–4432. 2010. View Article : Google Scholar : PubMed/NCBI
9	Terpos E, Morgan G, Dimopoulos MA, et al: International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol. 31:2347–2357. 2013. View Article : Google Scholar : PubMed/NCBI
10	Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbsin M, Xu NL, Mahuvakar VR, Andersen MR, et al: Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 33:e1792005. View Article : Google Scholar : PubMed/NCBI
11	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
12	International myeloma working group: Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 12l:749–757. 2003.
13	Cavo M, Rajkumar SV, Palumbo A, et al: International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 117:6063–6073. 2011. View Article : Google Scholar : PubMed/NCBI
14	Liu C, Yu J, Yu S, Lavker RM, Cai L, Liu W, Yang K, He X and Chen S: MicroRNA-21 acts as an oncomir through multiple targets in human hepatocellular carcinoma. J Hepatol. 53:98–107. 2010. View Article : Google Scholar : PubMed/NCBI
15	Xu J, Wu C, Che X, et al: Circulating microRNAs, miR-21, miR-122 and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog. 50:136–142. 2011. View Article : Google Scholar : PubMed/NCBI
16	Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, Drandi D, Taccioli C, Zanesi N, Alder H, Hagan JP, et al: MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA. 105:12885–12890. 2008. View Article : Google Scholar : PubMed/NCBI
17	Cabrita MA and Christofori G: Sprouty proteins, masterminds of receptor tyrosine kinase signaling. Angiogenesis. 11:53–62. 2008. View Article : Google Scholar : PubMed/NCBI
18	Lito P, Mets BD, Kleff S, O’Reilly S, Maher VM and McCormick JJ: Evidence that sprouty 2 is necessary for sarcoma formation by H-Ras oncogene-transformed human fibroblasts. J. Biol Chem. 283:2002–2009. 2008. View Article : Google Scholar
19	Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S and Allgayer H: MicroRNA-21(miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene. 27:2128–2136. 2008. View Article : Google Scholar
20	Wang X, Li C, Ju S, et al: Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation. Leuk Lymphoma. 52:1991–1998. 2011. View Article : Google Scholar : PubMed/NCBI
21	Löffler D, Brocke-Heidrich K, Pfeifer G, Stocsits C, Hackermüller J, Kretzschmar AK, Burger R, Gramatzki M, Blumert C, Bauer K, et al: Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood. 110:1330–1333. 2007. View Article : Google Scholar : PubMed/NCBI
22	Hu HY, Li KP, Wang XJ, Liu Y, Lu ZG, Dong RH, Guo HB and Zhang MX: Set9, NF-kappaB and microRNA-21 mediate berberine-induced apoptosis of human multiple myeloma cells. Acta Pharmacol Sin. 34:157–166. 2013. View Article : Google Scholar
23	Xiong Q, Zhong Q, Zhang J, Yang M, Li C, Zheng P, Bi LJ and Ge F: Identification of novel miR-21 target proteins in multiple myeloma cells by quantitative proteomics. J Proteome Res. 11:2078–2090. 2012. View Article : Google Scholar : PubMed/NCBI
24	Feng YH, Wu CL, Tsao CJ, et al: Deregulated expression of sprouty2 and microRNA-21 in human colon cancer: Correlation with the clinical stage of the disease. Cancer Biol Ther. 11:111–121. 2011. View Article : Google Scholar